Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 8518 participants.

Also called NCT05155137

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 8,518 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05155137
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05155137. Randomized; quadruple masking; primary purpose prevention. Start 2021-12-20 (actual); primary completion 2029-12-14 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)
Acronym
PROMOTE
Condition
Stroke
Condition
Cognitive Decline
Intervention (Drug)
Drug Capsule (Valsartan + Amlodipine + Rosuvastatin)
Intervention (Behavioral)
Stroke Riskometer
Lead sponsor
Hospital Moinhos de Vento (class: other)
Collaborator
Ministry of Health, Brazil (class: other government)
Collaborator
World Stroke Organization (class: not stated)

Record details

Record id
cardio:ct-nct05155137
Content hash
cd12cf9129ad8351c96bc96973331c7d106c6f65630b7e255def1410b7cbe908